乌苯美司联合放疗治疗早期鼻咽癌临床分析  

Clinical analysis of ubenimex combined with radiotherapy for early nasopharyngeal carcinoma

作　　者：龙斌[1] 苏加利[1] 刘利民[1] 杨新辉[1] 施晓焱 龙君 李树梁 周光华[1] Long Bin;Su Jiali;Liu Limin;Yang Xinhui;Shi Xiaoyan;Long Jun;Li Shuliang;Zhou Guanghua(Department of Oncology,the 163th Hospital of PLA,the Second Affiliated Hospital of Hunan Normal University,Changsha 410003,China;Department of Special Clinic,the 163th Hospital of PLA,the Second Affiliated Hospital of Hunan Normal University,Changsha 410003,China)

机构地区：[1]解放军第一六三医院湖南师范大学第二附属医院肿瘤科,长沙410003 [2]解放军第一六三医院湖南师范大学第二附属医院特诊科,长沙410003

出　　处：《肿瘤研究与临床》2018年第6期396-399,共4页Cancer Research and Clinic

摘　　要：目的 观察乌苯美司联合放疗治疗早期鼻咽癌患者的疗效及不良反应.方法 回顾性分析解放军第一六三医院/湖南师范大学第二附属医院肿瘤科2013年10月至2016年9月收治的早期鼻咽癌患者129例,分别采用乌苯美司联合三维适形放疗（研究组）和三维适形放疗（对照组）治疗,观察比较两组患者放射损伤反应、生命质量、疗效等.结果 治疗期间研究组较对照组乏力发生率低（57.8 %比75.4 %,χ2=4.481,P=0.034）,两组患者放疗结束时、放疗后3个月Karnofsky评分（χ2=6.345,P=0.042;χ2=6.382,P=0.041）及体质量变化（χ2=6.014,P=0.049;χ2=6.351,P=0.042）比较差异有统计学意义.研究组1年无远处转移生存率为92.2 %（59/64）,较对照组（80.0 %,52/65）升高（χ2=3.989,P=0.046）.结论 乌苯美司联合放疗治疗早期鼻咽癌,能提高患者的生命质量,并能减轻放射损伤反应,提高无转移生存率.Objective To observe the efficacy and adverse reactions of ubenimex combined with radiotherapy for the treatment of early nasopharyngeal carcinoma. Methods A total of 129 patients with early nasopharyngeal carcinoma who were admitted to the 163th Hospital of PLA, the Second Affiliated Hospital of Hunan Normal University from October 2013 to September 2016 were retrospectively analyzed. Three-dimensional conformal radiotherapy was used in the control group and ubenimex combined with three-dimensional conformal radiotherapy was taken in the study group. Radiation injury response, quality of life and therapeutic effects of patients in both groups were observed respectively. Results The fatigue incidence of the study group was lower than that of the control group （57.8 % vs. 75.4 %, χ2= 4.481, P= 0.034）. Karnofsky score （χ2=6.345, P=0.042; χ2=6.382, P=0.041, respectively） and weight change （χ2=6.014, P= 0.049; χ2= 6.351, P= 0.042, respectively） had statistical differences in both groups in the end of radiotherapy and 3 months after radiotherapy. 1-year non-distant metastasis survival rate （92.2 %, 59/64） in the study group was significantly higher than that in the control group （80.0 %, 52/65） （χ2=3.989, P=0.046）. Conclusion Ubenimex combined with radiotherapy for early nasopharyngeal carcinoma can improve the patients＇ quality of life, reduce the radiation injury response and increase the metastasis-free survival rate.

关 键 词：鼻咽肿瘤 乌苯美司 放射疗法 计算机辅助 生活质量 治疗结果 

分 类 号：R739.63[医药卫生—肿瘤]